Journal of Medicinal Chemistry p. 6169 - 6186 (2016)
Update date:2022-08-15
Topics:
Le Douaron, Gael
Ferrié, Laurent
Sepulveda-Diaz, Julia E.
Amar, Majid
Harfouche, Abha
Séon-Méniel, Blandine
Raisman-Vozari, Rita
Michel, Patrick P.
Figadère, Bruno
Parkinson's disease (PD) is a neurodegenerative disorder of aging characterized by motor symptoms that result from the loss of midbrain dopamine neurons and the disruption of dopamine-mediated neurotransmission. There is currently no curative treatment for this disorder. To discover druggable neuroprotective compounds for dopamine neurons, we have designed and synthesized a second-generation of quinoxaline-derived molecules based on structure-activity relationship studies, which led previously to the discovery of our first neuroprotective brain penetrant hit compound MPAQ (5c). Neuroprotection assessment in PD cellular models of our newly synthesized quinoxaline-derived compounds has led to the selection of a better hit compound, PAQ (4c). Extensive in vitro characterization of 4c showed that its neuroprotective action is partially attributable to the activation of reticulum endoplasmic ryanodine receptor channels. Most interestingly, 4c was able to attenuate neurodegeneration in a mouse model of PD, making this compound an interesting drug candidate for the treatment of this disorder.
View MoreContact:86-0510-85133006
Address:hubin road NO157
Shanghai Kangxin Chemical Co., Ltd
Contact:+86 21 60717227
Address:118,Ganbai Village,Waigang Town,Jiading District,Shanghai
Jinan Boss Chemical Industry Co., Ltd.
website:http://www.chemboss.com.cn
Contact:+86-531-58591595
Address:No2.Hualong Road, Jinan, China
Chongqing Rong&Quan Pharmaceutical Technology Co. , Ltd.
Contact:86-023-65268721
Address:No. 7, Manshanhong Village, Pingdingshan, Shapingba District, Chongqing Province, China
Contact:0571-
Address:zhejing
Doi:10.1021/bi00631a001
(1977)Doi:10.1016/j.catcom.2014.11.032
(2014)Doi:10.1016/j.jcat.2004.05.037
(2004)Doi:10.1021/om00065a023
(1982)Doi:10.1002/jhet.750
(2012)Doi:10.1016/j.cattod.2020.06.010
(2020)